Neurophth raises over $60M to advance gene therapies

By The Science Advisory Board staff writers

November 23, 2021 -- Neurophth Therapeutics has raised over $60 million in series C financing to advance gene therapies for ophthalmic diseases.

Neurophth is an integrated genomics medicine company whose leading investors include CMG-SDIC Capital, Sequoia Capital China, Sunshine Insurance, and China Merchant Bank International Capital.

Neurophth's lead candidate, NR082 (rAAV-ND4, NFS-01), is the first adeno-associated virus 2-based gene therapy to receive investigational new drug application approval in China, with the first patient being dosed in June 2021. NR082, a gene therapy candidate for the treatment of ND4-mediated Leber hereditary optic neuropathy, has been also granted the orphan drug designation by the U.S. Food and Drug Administration.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here